Literature DB >> 17575088

Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients.

Gianluca Colussi1, Cristiana Catena, Roberta Lapenna, Elisa Nadalini, Alessandra Chiuch, Leonardo A Sechi.   

Abstract

OBJECTIVE: An association between aldosterone and insulin resistance has been demonstrated in obesity and primary aldosteronism and in blacks with the metabolic syndrome. The aim of this study was to evaluate the relationship of plasma aldosterone with insulin sensitivity in white subjects. RESEARCH DESIGN AND METHODS: In 356 patients with essential hypertension and 102 normotensive control subjects of comparable age and BMI, we measured, after discontinuation of treatment, plasma active renin, aldosterone, cortisol, glucose, insulin, and C-peptide levels and calculated markers of insulin sensitivity. Direct assessment of insulin sensitivity was obtained in a subset of 64 hypertensive patients by a hyperinsulinemic clamp.
RESULTS: Hypertensive patients had significantly greater fasting plasma insulin and C-peptide concentrations and homeostasis model assessment (HOMA) indexes than normotensive control subjects. A positive association with increasing plasma aldosterone concentrations was demonstrated for plasma glucose, insulin, C-peptides, and HOMA. Assessment of insulin sensitivity by clamp showed a significant decrease of the metabolic clearance rate of glucose with increasing aldosterone levels. Significant correlations were found between plasma aldosterone, plasma insulin, and C-peptide levels, HOMA, and glucose metabolic clearance rate. Blood pressure and plasma potassium, plasma cortisol, and renin levels, but not BMI, were also directly correlated with plasma aldosterone. Multiple regression analysis showed that HOMA, together with plasma potassium, cortisol, and renin levels, was independently correlated with plasma aldosterone.
CONCLUSIONS: This study demonstrates a direct relationship between aldosterone, insulin resistance, and hyperinsulinemia in white subjects. In patients with hypertension, this relationship might contribute to maintenance of high blood pressure and increased cardiovascular risk.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17575088     DOI: 10.2337/dc07-0525

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  45 in total

Review 1.  The role of aldosterone in the metabolic syndrome.

Authors:  Marie Briet; Ernesto L Schiffrin
Journal:  Curr Hypertens Rep       Date:  2011-04       Impact factor: 5.369

2.  Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets.

Authors:  J M Luther; P Luo; M T Kreger; M Brissova; C Dai; T T Whitfield; H S Kim; D H Wasserman; A C Powers; N J Brown
Journal:  Diabetologia       Date:  2011-04-26       Impact factor: 10.122

Review 3.  Elevated prevalence of abnormal glucose metabolism in patients with primary aldosteronism: a meta-analysis.

Authors:  W Chen; F Li; C He; Y Zhu; W Tan
Journal:  Ir J Med Sci       Date:  2013-08-30       Impact factor: 1.568

Review 4.  The role of aldosterone in cardiovascular disease in people with diabetes and hypertension: an update.

Authors:  Guido Lastra-Gonzalez; Camila Manrique-Acevedo; James R Sowers
Journal:  Curr Diab Rep       Date:  2008-06       Impact factor: 4.810

Review 5.  Adrenal steroids and the metabolic syndrome.

Authors:  Stephen P Thomson; Craig S Stump; L Romayne Kurukulasuriya; James R Sowers
Journal:  Curr Hypertens Rep       Date:  2007-12       Impact factor: 5.369

Review 6.  The impacts of obesity on the cardiovascular and renal systems: cascade of events and therapeutic approaches.

Authors:  Zohreh Soltani; Vaughn Washco; Stephen Morse; Efrain Reisin
Journal:  Curr Hypertens Rep       Date:  2015-02       Impact factor: 5.369

7.  Differential Effects of Two Antialdosterone Agents on Glycemic Control.

Authors:  Rajesh Garg; Gail K Adler
Journal:  Endocrinology       Date:  2016-10       Impact factor: 4.736

Review 8.  The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy.

Authors:  Atsuhisa Sato
Journal:  Hypertens Res       Date:  2015-03-12       Impact factor: 3.872

9.  Increased aldosterone among HIV-infected women with visceral fat accumulation.

Authors:  Janet Lo; Sara E D Looby; Jeffrey Wei; Gail K Adler; Steven K Grinspoon
Journal:  AIDS       Date:  2009-11-13       Impact factor: 4.177

Review 10.  Genomic and rapid effects of aldosterone: what we know and do not know thus far.

Authors:  Milla Marques Hermidorff; Leonardo Vinícius Monteiro de Assis; Mauro César Isoldi
Journal:  Heart Fail Rev       Date:  2017-01       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.